Crossref
Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary
Digestive Medicine Research · 2020
DOI: 10.21037/dmr-20-100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Medicine Research, 2020. Verfasst von Hiroaki Tanioka und 1 weiteren Autor:innen.
Themen: Patientensicherheit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Tanioka, H., & Nagasaka, T. (2020). Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary. Digestive Medicine Research. https://doi.org/10.21037/dmr-20-100
Vancouver
Tanioka H, Nagasaka T. Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary. Digestive Medicine Research. 2020. doi:10.21037/dmr-20-100
BibTeX
@article{Tanioka2020,
author = {Tanioka, Hiroaki and Nagasaka, Takeshi},
title = {Lower incidence of adverse events about capecitabine and oxaliplatin from the GOIM 2802 study: a commentary},
journal = {Digestive Medicine Research},
year = {2020},
doi = {10.21037/dmr-20-100}
}
EUVIMED